Covered recipient · General Payments record
MAE B GUERRERO
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner
General Payments · PY2021–2024
$1,982.96
- Reported across 40 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $891.82 | 17 |
| Education | $8.45 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $459.33 | 11 |
| Acerta Pharma LLC | $284.02 | 4 |
| Gilead Sciences, Inc. | $121.81 | 1 |
| Amgen Inc. | $21.15 | 1 |
| Merck Sharp & Dohme Corporation | $13.96 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $34.92 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107261897 | CMS |
| ABBVIE INC. | $21.20 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107261899 | CMS |
| ABBVIE INC. | $8.45 | 03/05/2024 | Education | Undisputed | 01/23/2026 | 1107261901 | CMS |
| ABBVIE INC. | $149.56 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107261903 | CMS |
| ABBVIE INC. | $18.08 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107261905 | CMS |
| ABBVIE INC. | $20.11 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107261907 | CMS |
| ABBVIE INC. | $130.00 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107261909 | CMS |
| ABBVIE INC. | $30.20 | 05/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107261911 | CMS |
| ABBVIE INC. | $20.41 | 06/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107261913 | CMS |
| ABBVIE INC. | $12.56 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107261915 | CMS |
| ABBVIE INC. | $13.84 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107261917 | CMS |
| Amgen Inc. | $21.15 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117568929 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.00 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105418046 | CMS |
| AstraZeneca Pharmaceuticals LP | $26.50 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105565520 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.19 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104619760 | CMS |
| AstraZeneca Pharmaceuticals LP | $7.33 | 09/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105593787 | CMS |
| Gilead Sciences, Inc. | $121.81 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133655463 | CMS |
| Merck Sharp & Dohme LLC | $13.96 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141755610 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.